retatrutide phase 3 results october 2025 New data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide for the treatment of

Tirzepatide Tirzepatide, also known by the brand names Mounjaro and Zepbound, is an FDA-approved dual-action GLP-1/GIP receptor agonist made by Eli Lilly

Risks include: Unknown ingredients Incorrect dosing Contamination (especially dangerous with injections) Beyond safety, weight loss with GLP-1s requires medical guidance

Tirzepatide and semaglutide are both effective medications for weight loss, but they work in different ways

2008;478:136e42

20.1% 44.0% Up to 80% Once Weekly Metabolic Benefits Beyond Weight Mazdutide demonstrated improvements across multiple cardiometabolic markers that suggest effects extending well beyond simple caloric reduction

Store in a refrigerator (28C)